Table 1.
Baseline characteristics of women in the Women’s Health Initiative Coronary Heart Disease Biomarker Study.
| Estrogen+Progesterone (n=588) | Estrogen alone (n=390) | Combined Trials (n=978) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Cases (n=158) | Controls (n=430) | Cases (n=113) | Controls (n=277) | Cases (n=271) | Controls (n=707) | ||||
|
| |||||||||
| Characteristic | N (%) | N (%) | P* | N (%) | N (%) | P* | N (%) | N (%) | P* |
| Age at screen (mean years), (SD) | 65.8 (7.3) | 66.6 (6.8) | 0.25 | 67.0 (6.6) | 66.2 (6.5) | 0.32 | 66.3 (7.0) | 66.4 (6.7) | 0.77 |
|
| |||||||||
| Race/ethnicity | 0.26 | 0.41 | 0.78 | ||||||
| White | 141 (89.2%) | 379 (88.1%) | 86 (76.1%) | 214 (77.3%) | 227 (83.8%) | 593 (83.9%) | |||
| Black | 7 (4.4%) | 24 (5.6%) | 16 (14.2%) | 42 (15.2%) | 23 (8.5%) | 66 (9.3%) | |||
| Hispanic | 5 (3.2%) | 17 (4.0%) | 6 (5.3%) | 14 (5.1%) | 11 (4.1%) | 31 (4.4%) | |||
| Am Indian | 1 (0.6%) | 1 (0.2%) | 0 (0.0%) | 2 (0.7%) | 1 (0.4%) | 3 (0.4%) | |||
| Asian/PI | 0 (0.0%) | 6 (1.4%) | 3 (2.7%) | 1 (0.4%) | 3 (1.1%) | 7 (1.0%) | |||
| Unknown | 4 (2.5%) | 3 (0.7%) | 2 (1.8%) | 4 (1.4%) | 6 (2.2%) | 7 (1.0%) | |||
|
| |||||||||
| Hormone use | 0.33 | 0.38 | 0.21 | ||||||
| Never | 116 (73.4%) | 322 (74.9%) | 69 (61.1%) | 155 (56.0%) | 185 (68.3%) | 477 (67.5%) | |||
| Past | 36 (22.8%) | 81 (18.8%) | 36 (31.9%) | 90 (32.5%) | 72 (26.6%) | 171 (24.2%) | |||
| Current‡ | 6 (3.8%) | 27 (6.3%) | 8 (7.1%) | 32 (11.6%) | 14 (5.2%) | 59 (8.3%) | |||
|
| |||||||||
| Body mass index (mean kg/m2), (SD) | 28.7 (6.0) | 27.7 (5.8) | 0.07 | 30.2 (6.1) | 29.3 (5.5) | 0.18 | 29.3 (6.1) | 28.4 (5.7) | 0.02 |
|
| |||||||||
| Smoking | <.001 | 0.001 | <.001 | ||||||
| Never | 71 (44.9%) | 239 (55.6%) | 54 (47.8%) | 147 (53.1%) | 125 (46.1%) | 386 (54.6%) | |||
| Past | 50 (31.6%) | 154 (35.8%) | 31 (27.4%) | 99 (35.7%) | 81 (29.9%) | 253 (35.8%) | |||
| Current | 32 (20.3%) | 32 (7.4%) | 25 (22.1%) | 22 (7.9%) | 57 (21.0%) | 54 (7.6%) | |||
|
| |||||||||
| Treated diabetes | 16 (10.1%) | 18 (4.2%) | 0.006 | 23 (20.4%) | 14 (5.1%) | <.001 | 39 (14.4%) | 32 (4.5%) | <.001 |
|
| |||||||||
| Hypertension§ | 79 (50.0%) | 158 (36.7%) | 0.004 | 67 (59.3%) | 127 (45.8%) | 0.02 | 146 (53.9%) | 285 (40.3%) | <.001 |
|
| |||||||||
| Treated cholesterol | 26 (16.5%) | 54 (12.6%) | 0.28 | 18 (15.9%) | 33 (11.9%) | 0.48 | 44 (16.2%) | 87 (12.3%) | 0.14 |
|
| |||||||||
| Statin use | 13 (8.2%) | 23 (5.3%) | 0.20 | 10 (8.8%) | 20 (7.2%) | 0.58 | 23 (8.5%) | 43 (6.1%) | 0.18 |
|
| |||||||||
| Aspirin use (≥80 mg/d) | 31 (19.6%) | 90 (20.9%) | 0.73 | 25 (22.1%) | 53 (19.1%) | 0.50 | 56 (20.7%) | 143 (20.2%) | 0.88 |
|
| |||||||||
| History of bilateral oophorectomy | 0 (0.0%) | 1 (0.2%) | 0.40 | 50 (44.2%) | 112 (40.4%) | 0.50 | 50 (18.5%) | 113 (16.0%) | 0.57 |
*
Cases vs. Controls
‡
Required a 3-month washout prior to randomization.
§
Hypertension defined as self-report of treated hypertension ever, systolic BP ≥ 140, or diastolic BP ≥ 90.